Fig. 2.

Incidence rates per 1000 PY for A infection, B malignancy, and C MACE/VTE outcome events of interest in the AA and matched non-AA cohorts. ^aThe total number of patients at risk (i.e., denominator) differed depending on whether the outcome event was acute or chronic (including all malignancy events, MACE, DVT, PE, and ATE). Therefore, the denominator was not always 8784 for the AA cohort or 26,352 for the non-AA cohort. ^bExcluding nonmelanoma skin cancer. AA alopecia areata, ATE arterial thromboembolism, BCC basal cell carcinoma, CABG coronary artery bypass graft, DVT deep vein thrombosis, IR incidence rate, MACE major adverse cardiovascular event, MI myocardial infarction, PCI percutaneous coronary intervention, PE pulmonary embolism, PY patient-years, SCC squamous cell carcinoma, VTE venous thromboembolic event